AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16205924 — intervention group
Group type: COMPARATOR
Intervention: 9AC administered under fasting conditions
Number of subjects: 16
Study 12666001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine
Number of subjects: 45
Study 12666001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine + 50 microg clonidine
Number of subjects: 45
Study 12666001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12666001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (combined with morphine)
Number of subjects: 45
Study 10750638 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC)
Number of subjects: 19
Study 10750638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9167105 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 942
Study 9167105 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (Humulin R)
Number of subjects: 942
Study 8242291 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 20
Study 8242291 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy
Number of subjects: 20
Study 2953174 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.04 microgram/kg/min) in hypertensive men (n = 13)
Number of subjects: 79
Study 2953174 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.04 microgram/kg/min) in normotensive men (n = 12)
Number of subjects: 79
Study 2953174 — intervention group
Group type: COMPARATOR
Intervention: Infused saline in normotensive subjects (n = 12)
Number of subjects: 79
Study 2953174 — intervention group
Group type: COMPARATOR
Intervention: Comparison of venous platelets in hypertensive men (n = 35)
Number of subjects: 79
Study 2953174 — intervention group
Group type: COMPARATOR
Intervention: Plasma concentration of beta‐thromboglobulin (BTG) in hypertensive men (n = 35)
Number of subjects: 79
Study 2953174 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BTG concentration in venous vs arterial blood in normotensive subjects (n = 44)
Number of subjects: 79
Study 30612549 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention at the workplace
Number of subjects: 6
Study 29480363 — intervention group
Group type: EXPERIMENTAL
Intervention: US + LLLT
Number of subjects: 42
Study 29480363 — intervention group
Group type: EXPERIMENTAL
Intervention: TE + US + LLLT
Number of subjects: 42
Study 29480363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 26588208 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically infected silicone stents (n = 10)
Number of subjects: 19
Study 26588208 — intervention group
Group type: COMPARATOR
Intervention: Clinically noninfected silicone stents (n = 9)
Number of subjects: 19
Study 25089313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 56
Study 25089313 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 56
Study 21883302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable condition
Number of subjects: 76
Study 21883302 — intervention group
Group type: EXPERIMENTAL
Intervention: Upwardly unstable condition
Number of subjects: 76
Study 21883302 — intervention group
Group type: EXPERIMENTAL
Intervention: Downwardly unstable condition
Number of subjects: 76
Study 19469799 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg GTPs twice daily
Number of subjects: 56
Study 19469799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 19469799 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg GTPs
Number of subjects: 56
Study 17366092 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by a social worker focused on motivation, goal setting, and planning of return to work.
Number of subjects: 264
Study 17366092 — intervention group
Group type: COMPARATOR
Intervention: Standard case management offered by municipalities (Control group).
Number of subjects: 264
Study 12655904 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting program
Number of subjects: 44
Study 12655904 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 44
Study 10927051 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (effectiveness of 2.0)
Number of subjects: 0
Study 10927051 — intervention group
Group type: COMPARATOR
Intervention: Constant-sequence design
Number of subjects: 0
Study 10927051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating-sequence design
Number of subjects: 0
Study 9574145 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8268525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (50 mg/kg administered just before and after CPB, and every 90 minutes during CPB)
Number of subjects: 157
Study 8268525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 157
Study 8268525 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 157
Study 2421015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-directed transperineal needle biopsy
Number of subjects: 55
Study 2421015 — intervention group
Group type: COMPARATOR
Intervention: Conventional transperineal biopsy
Number of subjects: 55
Study 30747489 — intervention group
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral drug-coated balloon (DCB)
Number of subjects: 100
Study 30747489 — intervention group
Group type: COMPARATOR
Intervention: Uncoated percutaneous transluminal angioplasty (PTA)
Number of subjects: 100
Study 28032813 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Life (COL) program
Number of subjects: 635
Study 28032813 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 635
Study 27335282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise at 50% peak oxygen uptake in the heat (37°C and 50% RH) in the morning (0600)
Number of subjects: 19
Study 27335282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise at 50% peak oxygen uptake in the heat (37°C and 50% RH) in the evening (1800)
Number of subjects: 19
Study 25398294 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 30
Study 25398294 — intervention group
Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 30
Study 22381987 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized insulin dose calculator
Number of subjects: 300
Study 22381987 — intervention group
Group type: COMPARATOR
Intervention: Control (paper protocol)
Number of subjects: 300
Study 20153761 — intervention group
Group type: EXPERIMENTAL
Intervention: Size judgement task
Number of subjects: 0
Study 20153761 — intervention group
Group type: EXPERIMENTAL
Intervention: Animateness judgement task
Number of subjects: 0
Study 18325458 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (T) plus usual care (UC)
Number of subjects: 48
Study 15988130 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 31
Study 15988130 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched for gender, age, and smoking habits)
Number of subjects: 31
Study 14582102 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg intravenously
Number of subjects: 37
Study 14582102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 37
Study 10478579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal continuous subcutaneous apomorphine infusion
Number of subjects: 8
Study 10478579 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion with normal saline
Number of subjects: 8
Study 8734765 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial hemiplegic migraine linked to chromosome 19
Number of subjects: 66
Study 8734765 — intervention group
Group type: COMPARATOR
Intervention: Familial hemiplegic migraine not linked to chromosome 19
Number of subjects: 66
Study 1878231 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 40
Study 1878231 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 40
Study 1878231 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 40
Study 1878231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6311306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (3 mg orally three times a day, starting the day before cis-platinum and ending the day after)
Number of subjects: 20
Study 6311306 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (12.5 mg IM, 15 minutes before cis-platinum)
Number of subjects: 20
Study 6311306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 20
Study 6311306 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 20
Study 6311306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone and Chlorpromazine
Number of subjects: 20
Study 30404544 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical product based on 0.8% piroxicam and 50+ solar filters (ACTX), applied twice a day after C-PDT or DL-PDT.
Number of subjects: 68
Study 30404544 — intervention group
Group type: COMPARATOR
Intervention: Standard Sunscreens (SS group) with SPF50+ or SPF100+ associated with photolyase.
Number of subjects: 68
Study 30404544 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTX
Number of subjects: 68
Study 30404544 — intervention group
Group type: COMPARATOR
Intervention: SS group
Number of subjects: 68
Study 28272290 — intervention group
Group type: COMPARATOR
Intervention: Continuous interscalene block
Number of subjects: 75
Study 28272290 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous supraclavicular block
Number of subjects: 75
Study 28272290 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suprascapular block
Number of subjects: 75
Study 25017941 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Restoration (WR) hospitalization
Number of subjects: 82
Study 25017941 — intervention group
Group type: COMPARATOR
Intervention: Medical Stabilization (MS) hospitalization
Number of subjects: 82
Study 25259704 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 2962
Study 25259704 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 2962
Study 25259704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2962
Study 25259704 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2962
Study 25259704 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF, FTC/TDF, Placebo
Number of subjects: 2962
Study 21813629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg at induction followed by 0.3 mg/kg/h infusion)
Number of subjects: 64
Study 21813629 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline equivalent volume)
Number of subjects: 64
Study 19019049 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (35 microg/hour) plus epidural morphine and ropivacaine (200 mg + 2 mg)
Number of subjects: 86
Study 19019049 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine and ropivacaine (200 mg + 2 mg) with placebo patch
Number of subjects: 86
Study 17452486 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of rifampin (600 mg)
Number of subjects: 50
Study 17452486 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of rifampin (450 mg)
Number of subjects: 50
Study 14960009 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 921
Study 14960009 — intervention group
Group type: COMPARATOR
Intervention: Brushing
Number of subjects: 921
Study 10529580 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneippism (custom‐tailored combination of therapies comprising hydrotherapy, kinesiotherapy, phytotherapy, dietetics, 'ordnungstherapie', and continued disease‐specific standard treatment)
Number of subjects: 363
Study 10529580 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneippism
Number of subjects: 363
Study 8690110 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogeneous endometrial pattern
Number of subjects: 175
Study 8690110 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaminar endometrial pattern
Number of subjects: 175
Study 1755466 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion program
Number of subjects: 0
Study 1755466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactational amenorrhea method
Number of subjects: 0
Study 1755466 — intervention group
Group type: EXPERIMENTAL
Intervention: Total family planning coverage
Number of subjects: 0
Study 6978270 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 800 mg daily
Number of subjects: 40
Study 6978270 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 100 mg daily
Number of subjects: 40
Study 31896686 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil or rituximab or chlorambucil plus rituximab (systemic treatment)
Number of subjects: 688
Study 31896686 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment (validation set)
Number of subjects: 688
Study 31242926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise intervention based on internet and social media software (CEIBISMS)
Number of subjects: 60
Study 31242926 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment and rehabilitation
Number of subjects: 60
Study 28323948 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 45
Study 28323948 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 100 mg BID
Number of subjects: 45
Study 28323948 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg BID
Number of subjects: 45
Study 28323948 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg BID
Number of subjects: 45
Study 28323948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25960024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure, knee-length graduated compression stockings
Number of subjects: 219
Study 25960024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure, thigh-length graduated compression stockings
Number of subjects: 219
Study 25960024 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-pressure, knee-length graduated compression stockings
Number of subjects: 219
Study 25960024 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 219
Study 22646157 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily (loading dose 300 mg) plus indobufen 100 mg twice a day (group A)
Number of subjects: 42
Study 22646157 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily after 300 mg loading dose (group B)
Number of subjects: 42
Study 21136226 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic causal information
Number of subjects: 110
Study 21136226 — intervention group
Group type: COMPARATOR
Intervention: Control topic
Number of subjects: 110
Study 19631119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Zyoptix aspheric algorithm (aspheric group)
Number of subjects: 170
Study 19631119 — intervention group
Group type: COMPARATOR
Intervention: Bilateral conventional Zyoptix Tissue Saving algorithm (control group)
Number of subjects: 170
Study 17030113 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscadine grape wine (MW)
Number of subjects: 0
Study 17030113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized muscadine grape wine (Dz‐W)
Number of subjects: 0
Study 17030113 — intervention group
Group type: COMPARATOR
Intervention: Muscadine grape juice (MJ)
Number of subjects: 0
Study 15894901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme (4-month duration)
Number of subjects: 241
Study 15894901 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 241
Study 15894901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme
Number of subjects: 241
Study 10598211 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 0
Study 10598211 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 8590519 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week intensive treatment program (n = 55)
Number of subjects: 106
Study 8590519 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (n = 51)
Number of subjects: 106
Study 1770472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Patient education programme (two educational talks and one tutorial meeting)
Number of subjects: 287
Study 1770472 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No patient education programme
Number of subjects: 287
Study 1770472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 287
Study 1770472 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 287
Study 6751116 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 60 mg/kg body weight in three divided doses orally
Number of subjects: 11
Study 6751116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6751116 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 11
Study 31568119 — intervention group
Group type: EXPERIMENTAL
Intervention: Preset telephone alarm
Number of subjects: 79
Study 31568119 — intervention group
Group type: COMPARATOR
Intervention: No alarm
Number of subjects: 79
Study 30537752 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Tai Chi (VRTC) exercise program, conducted twice weekly for 6 months
Number of subjects: 60
Study 30537752 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Tai Chi (VRTC) exercise program
Number of subjects: 60
Study 30537752 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 27236286 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleaved teaching method
Number of subjects: 40
Study 27236286 — intervention group
Group type: COMPARATOR
Intervention: Massed teaching method
Number of subjects: 40
Study 27236286 — intervention group
Group type: COMPARATOR
Intervention: Interleaved method for first-year students
Number of subjects: 40
Study 27236286 — intervention group
Group type: COMPARATOR
Intervention: Massed method for first-year students
Number of subjects: 40
Study 27236286 — intervention group
Group type: COMPARATOR
Intervention: Interleaved method for second-year students
Number of subjects: 40
Study 27236286 — intervention group
Group type: COMPARATOR
Intervention: Massed method for second-year students
Number of subjects: 40
Study 24628747 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen (5 mg/500 mg)
Number of subjects: 0
Study 24628747 — intervention group
Group type: COMPARATOR
Intervention: Codeine/acetaminophen (30 mg/300 mg)
Number of subjects: 0
Study 24628747 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen
Number of subjects: 0
Study 24628747 — intervention group
Group type: COMPARATOR
Intervention: Codeine/acetaminophen
Number of subjects: 0
Study 22525654 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Protocol (EP) - Resistance exercise session with 3 sets of 8 to 10 repetitions
Number of subjects: 30
Study 22525654 — intervention group
Group type: COMPARATOR
Intervention: Control Protocol (CP) - Same procedures as EP but without exercises
Number of subjects: 30
Study 20071560 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2,000 mg/day)
Number of subjects: 16
Study 20071560 — intervention group
Group type: COMPARATOR
Intervention: Exercise (40 min at 65% Vo(2peak))
Number of subjects: 16
Study 20071560 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Exercise
Number of subjects: 16
Study 17905017 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 40
Study 17905017 — intervention group
Group type: EXPERIMENTAL
Intervention: IDUS
Number of subjects: 40
Study 16085529 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarettes
Number of subjects: 307
Study 16085529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmenthol cigarettes
Number of subjects: 307
Study 16085529 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tobacco exposure measures
Number of subjects: 307
Study 16085529 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender x race x menthol interaction
Number of subjects: 307
Study 12107206 — intervention group
Group type: EXPERIMENTAL
Intervention: im T enanthate 100 mg/wk plus daily oral placebo (T)
Number of subjects: 32
Study 12107206 — intervention group
Group type: COMPARATOR
Intervention: im placebo/wk plus 125 microg daily oral levonorgestrel (LNG)
Number of subjects: 32
Study 12107206 — intervention group
Group type: EXPERIMENTAL
Intervention: im T enanthate 100 mg/wk plus 125 microg daily oral LNG (T + LNG)
Number of subjects: 32
Study 12107206 — intervention group
Group type: COMPARATOR
Intervention: im placebo/wk plus daily oral placebo
Number of subjects: 32
Study 10053098 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL‐6 plus G‐CSF
Number of subjects: 50
Study 10053098 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus G‐CSF
Number of subjects: 50
Study 8821076 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion-tablet
Number of subjects: 0
Study 8821076 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion-capsule
Number of subjects: 0
Study 8821076 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion-infusion
Number of subjects: 0
Study 2286454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g p.o. each on the evening before and after the operation)
Number of subjects: 61
Study 2286454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30247316 — intervention group
Group type: EXPERIMENTAL
Intervention: QFN-CMV directed valganciclovir prophylaxis (5-11 months post-LTx)
Number of subjects: 118
Study 30247316 — intervention group
Group type: COMPARATOR
Intervention: Fixed-duration valganciclovir prophylaxis (5 months)
Number of subjects: 118